HIGHLIGHTS
Revenue reached
The newest product in the portfolio, Vyepti®, grew 49% since the fourth quarter of 2020. The brand continues its strong momentum since launch in the second quarter of 2020. Regulatory review is ongoing in 12 markets.
Strategic brand performance:
- Revenue of Abilify Maintena®:
DKK 584 million (flat in local currencies, -5% reported) -
Revenue of Brintellix®/Trintellix®:
DKK 804 million (up 7% in local currencies, -2% reported) -
Revenue of Rexulti®/Rxulti®:
DKK 672 million (up 4% in local currencies, -6% reported) -
Revenue of Vyepti reached
DKK 76 million following the launch in theU.S. inApril 2020
- Revenue of Abilify Maintena®:
Market performance:
- Revenue in
North America :DKK 2,118 million (up 2% in local currencies, -11% reported) -
Revenue in International Markets:
DKK 1,162 million (up 4% in local currencies, -6% reported) -
Revenue in
Europe :DKK 844 million (-5% and -6% in local currencies and reported, respectively)
- Revenue in
In connection with the financial report, Lundbeck's President and CEO
"Lundbeck continues to deliver robust financial performance in a world impacted by the pandemic still impeding patient's ability to seek care normally. We are very pleased to see good Vyepti growth in the
Key figures:
DKK million | Q1 2021 | Q1 2020 | Growth |
Core Revenue* | 4,273 | 4,564 | (6%) |
Core EBIT* | 1,253 | 1,357 | (8%) |
Core EPS* | 4.65 | 4.89 | (5%) |
Core EBIT margin* | 29.3% | 29.7% | |
Reported Revenue | 4,273 | 4,564 | (6%) |
Reported EBIT | 882 | 263 | 235% |
Reported EPS | 3.13 | 0.46 | 578% |
Reported EBIT margin | 20.6% | 5.8% |
For definition of the measures "Core Revenue", "Core EBIT", "Core EBIT margin" and "Core EPS", see note 4 Core reporting
Compared to the first quarter of 2020, which benefitted from extraordinary COVID-19 related stocking in several markets, the first quarter of 2021 saw a return to more normal consumer buying patterns seen pre-pandemic. The increased currency depreciation in key markets had an overall negative impact of 4% on sales growth.
Strong headline results reported from the RECONNECT study in patients with depression and generalized anxiety and from the real-world evidence study RELIEVE both with Brintellix/Trintellix and which support the overall strength of the product.
New data from the RELIEF-study presented at 2021
Core EBIT reached
The financial guidance for 2021 is maintained. Lundbeck expects revenue to reach
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/lundbeck-delivers-a-solid-ebit-of-dkk-882-million-and-vyepti-is-off-to-a-good-start,c3344707
https://mb.cision.com/Main/18215/3344707/1415858.pdf
(c) 2021 Cision. All rights reserved., source